Retatrutide goes further by adding glucagon receptor activation to the mix, creating a synergistic effect that produces greater metabolic changes than either dual or single agonists alone
At Continental Hospitals, our expert endocrinologists and internal medicine specialists provide advanced evaluation and comprehensive care for hormonal and metabolic disorders
The FDA describes a compounded drug as a medicine that is customized to the specific needs of an individual patient
Lancet Diabetes Endocrinol 6(4):275286 Rossing P, Baeres FMM, Bakris G, Bosch-Traberg H, Gislum M, Gough SCL et al (2023) The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
It's not known if they cause these tumors in humans, but people with a personal or family history of thyroid cancer are ineligible for the medications
In a 48-week Phase 2 trial published in 2023, Retatrutide produced some dramatic weight loss results